Skip to content
Save up to 80%

Spiriva

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Select pack Package Per unit Price

Free delivery on orders from R 3 930.00, free express delivery from R 5 895.00

Secure Payments
Track your order
Best price guarantee

Spiriva is a prescription maintenance inhaler for adults with COPD and selected patients with asthma. Its active ingredient, tiotropium bromide, keeps airway muscles relaxed for about 24 hours by reducing cholinergic bronchoconstriction.

Description

Spiriva is a prescription maintenance inhaler containing tiotropium bromide for adults with COPD and selected patients with asthma. It keeps airway muscles relaxed for about 24 hours, helping reduce airflow limitation and daily breathing symptoms. Spiriva Respimat is inhaled as a soft mist through a reusable device.

Composition

Spiriva Respimat contains tiotropium bromide, supplied as tiotropium bromide monohydrate in an inhalation solution. Each actuation delivers 2.5 micrograms of tiotropium. The product is a long-acting muscarinic antagonist, also called a LAMA, and an inhaled anticholinergic bronchodilator. [1]

Tiotropium bromide monohydrate blocks muscarinic receptors in the smooth muscle surrounding the airways. Acetylcholine normally stimulates these receptors and can cause airway narrowing. By reducing that signal, tiotropium helps keep the bronchial tubes open for an extended period.

The medicine acts locally in the lungs after inhalation. Its long duration allows once-daily maintenance treatment, while its formulation is designed for delivery as a slow-moving soft mist rather than a conventional aerosol burst.

Active ingredient and drug class

The key pharmaceutical facts are:

  • Active ingredient: tiotropium bromide
  • Chemical form: tiotropium bromide monohydrate
  • Drug class: long-acting muscarinic antagonist
  • Therapeutic group: inhaled anticholinergic bronchodilator
  • Route: oral inhalation through the Respimat inhaler
  • Strength: 2.5 micrograms per actuation
  • Usual daily amount: two inhalations once daily, providing 5 micrograms of tiotropium

The medicine is designed for regular control, not immediate relief.

Keep the inhaler upright when preparing an inhalation. A level, controlled press makes it easier to release the mist while breathing in slowly.

Dosage and usage

The recommended Spiriva Respimat regimen is two inhalations once daily, taken at about the same time each day. Each inhalation delivers 2.5 micrograms, so the total daily dose is 5 micrograms.

Use the device in this sequence:

  1. Keep the inhaler upright and remove the clear base.
  2. Insert the cartridge fully into the inhaler before first use.
  3. Replace the base and follow the preparation steps supplied for a new device.
  4. Prime the inhaler until a visible mist appears, then repeat the preparation steps as directed for first use.
  5. Turn the clear base in the direction indicated until it clicks.
  6. Open the cap.
  7. Breathe out away from the mouthpiece.
  8. Seal your lips around the mouthpiece without covering the air vents.
  9. Start a slow, deep breath through the mouth while pressing the dose-release button.
  10. Hold the breath briefly, if comfortable, then breathe normally.
  11. Repeat the turn, open, press sequence for the second inhalation.

The device must be primed before the first therapeutic dose. A common practical error is pressing the button before beginning a slow inhalation, which leaves much of the mist in the air instead of the lungs.

Another frequent error is taking only one inhalation daily. The prescribed Spiriva Respimat dose requires two inhalations together once a day. If a dose is missed, take it when remembered unless the next scheduled dose is close; do not take two daily doses at once.

Do not swallow the inhalation solution. Do not spray it into the eyes. If the mist enters the eyes and causes eye pain, blurred vision, coloured halos, or redness, urgent clinical assessment is needed because these symptoms can indicate acute narrow-angle glaucoma.

Practise the sequence with a nurse, doctor, or respiratory therapist before relying on the inhaler alone. The most common technique failure is breathing too quickly during the press.

How it works

Airway narrowing involves contraction of bronchial smooth muscle. Acetylcholine contributes to this contraction by stimulating muscarinic receptors, especially the M3 receptor on airway smooth muscle. Tiotropium occupies these receptors and reduces cholinergic bronchoconstriction.

The result is bronchodilation. Airflow can move more easily through the larger and smaller airways, which may reduce wheezing and breathlessness and improve measured lung function.

Tiotropium differs from inhaled corticosteroids because it does not primarily suppress airway inflammation. It also differs from short-acting beta-2 agonists, which stimulate beta receptors for faster but shorter bronchodilation. Spiriva provides prolonged antimuscarinic action.

Do not use extra Spiriva inhalations for sudden breathlessness. More frequent use does not provide the rapid relief expected from a short-acting reliever and can increase anticholinergic exposure.

Indications

Spiriva is used as maintenance bronchodilator therapy for chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. COPD causes persistent airflow limitation, cough, sputum production, wheezing, and breathlessness. Regular tiotropium treatment can improve lung function and reduce the impact of symptoms during daily activity. [2]

Spiriva Respimat is also used as add-on maintenance treatment for asthma in patients whose symptoms remain insufficiently controlled with inhaled corticosteroid therapy, with or without another controller medicine. The exact place of tiotropium in asthma treatment depends on age, disease severity, inhaled corticosteroid use, and the patient’s response.

Clinical use Treatment role Key limitation
COPD Once-daily maintenance bronchodilation Does not treat a sudden severe attack
Asthma Add-on controller treatment in selected patients Does not replace inhaled corticosteroids
Acute breathlessness Not a rescue treatment A prescribed reliever inhaler is used instead

Spiriva does not work like a short-acting reliever inhaler. Sudden chest tightness, rapidly worsening breathlessness, blue lips, or difficulty speaking requires urgent medical assessment and the patient’s emergency action plan.

The VivaTinA-asthma study programme evaluated tiotropium as an additional long-acting bronchodilator in asthma. Its clinical role remains supportive: it is added to established anti-inflammatory treatment when asthma control remains inadequate, rather than used as the sole controller for persistent airway inflammation.

Comparison

The product described here is Spiriva Respimat, a solution inhaled as a soft mist. The reusable Respimat inhaler uses a cartridge and mechanical energy to produce a slow-moving cloud. This can help patients who find it difficult to coordinate a forceful inhalation with a conventional pressurised inhaler.

Spiriva HandiHaler uses a different delivery method: tiotropium powder is inhaled from a capsule placed into a dry-powder device. The capsule is punctured inside the device and is not swallowed. The two platforms deliver tiotropium through different inhalation techniques, so device training matters.

The TIOSPIR study compared tiotropium delivered through Respimat and HandiHaler in people with COPD. The study found similar clinical outcomes for the doses evaluated, including no significant difference in mortality between the studied treatment groups. [3]

Delivery system Inhaled medicine Practical technique
Respimat Soft mist inhalation solution Turn, open, press while breathing in slowly
HandiHaler Dry powder from a capsule Load, puncture, and inhale forcefully through the device

The comparison is clinical rather than a catalogue choice. A prescriber considers inspiratory ability, hand coordination, dexterity, cognition, previous inhaler training, and the patient’s ability to use one device reliably.

Patients with weak inspiratory flow may find a soft-mist system easier than a dry-powder device. Patients who cannot coordinate the press-and-breathe sequence may need repeated demonstration or a different inhaler approach.

Contraindications

Spiriva is not suitable for a person with a known allergy to tiotropium, atropine, ipratropium, oxitropium, or related anticholinergic substances. It is also unsuitable for anyone with a previous serious reaction to an ingredient in the inhalation formulation.

Extra caution is needed in the following situations:

  • Narrow-angle glaucoma or a history of acute glaucoma
  • Urinary retention or bladder-outflow obstruction
  • Enlarged prostate with difficult urination
  • Severe kidney impairment
  • Previous rapid heartbeat or clinically significant arrhythmia
  • Known sensitivity to benzalkonium chloride
  • Pregnancy or breastfeeding, when treatment benefit and potential risk require individual assessment

Spiriva Respimat contains benzalkonium chloride as an excipient. In susceptible people, inhaled benzalkonium chloride can cause bronchospasm. A history of sensitivity to inhaled preservatives should be raised before treatment.

Potential additive anticholinergic effects can occur with other medicines that have antimuscarinic properties, including some bladder medicines, gastrointestinal antispasmodics, and selected medicines used for movement disorders. Combining these treatments may increase dry mouth, constipation, blurred vision, urinary retention, or confusion.

When this is not for you

Not for you if you need a rescue inhaler for sudden breathlessness or cannot use the device safely.

The medicine can worsen urinary retention. New difficulty starting urination, painful bladder fullness, or inability to pass urine requires urgent medical attention.

Acute narrow-angle glaucoma may present with eye pain, red eyes, blurred vision, or coloured rings around lights. These symptoms should not be managed by taking the next dose and waiting for improvement.

Paradoxical bronchospasm means that airway narrowing occurs immediately after inhalation rather than improving. Stop using the inhaler and seek urgent medical care if breathing suddenly becomes worse after a dose. The same warning applies to severe swelling of the lips, face, tongue, or throat.

Side effects

Dry mouth is among the most recognised anticholinergic effects of tiotropium. Cough, sore throat, constipation, headache, palpitations, and dizziness can also occur. The severity varies, and some symptoms improve as the body adapts to regular inhalation.

Common effects include:

  • Dry mouth or throat
  • Cough after inhalation
  • Sore throat or hoarseness
  • Headache
  • Dizziness
  • Constipation
  • Nausea
  • Difficulty sleeping
  • Awareness of the heartbeat

Dry mouth can make swallowing and speaking uncomfortable. Frequent small sips of water, sugar-free gum, or sugar-free lozenges may help. Excessive sugary sweets increase dental risk, especially when dry mouth persists.

Dizziness can be more noticeable when standing quickly. Sitting down before the inhalation and rising slowly can reduce the chance of losing balance. Persistent dizziness, fainting, or a fast irregular heartbeat requires medical review.

Tiotropium is inhaled, but some medicine can reach the mouth and throat. Rinsing the mouth after inhalation may improve unpleasant taste or throat irritation. Unlike inhaled corticosteroids, tiotropium does not commonly cause oral thrush through the same local steroid mechanism.

If dry mouth continues, watch for cracked lips, difficulty swallowing, or new dental sensitivity. These are practical signs that the symptom is affecting hydration and oral comfort rather than being a minor nuisance.

Serious reactions are uncommon but require prompt attention. Sudden worsening wheezing immediately after inhalation may represent paradoxical bronchospasm. Facial swelling, tongue swelling, widespread rash, or difficulty breathing may indicate a serious allergic reaction.

Common mistakes

Several errors reduce the amount of medicine reaching the lungs:

  • Using Spiriva only on days with symptoms
  • Taking one inhalation instead of two
  • Treating Spiriva as an emergency reliever
  • Pressing the dose button before starting a slow inhalation
  • Breathing out through the mouthpiece after pressing
  • Failing to prime a new inhaler
  • Spraying the mist toward the eyes
  • Swallowing a capsule intended for a dry-powder device
  • Sharing an inhaler
  • Adding another anticholinergic medicine without checking for additive effects

A missed dose should not be replaced by extra inhalations. Taking multiple doses together increases exposure without creating immediate rescue treatment.

One subtle mistake is stopping after a few days because breathing has not changed dramatically. Maintenance bronchodilators are assessed through regular symptom patterns and lung-function review, not by a single inhalation.

Another is assuming that a clean mouthpiece proves correct inhalation. A person can release the full mist outside the lungs while the device still appears to work normally.

What doctors say

In clinical practice, doctors usually describe Spiriva as a controller medicine that works best when taken every day. Missing doses can make its benefit seem inconsistent, even when the pharmacological response is appropriate.

A respiratory clinician will often assess inhaler technique before increasing treatment. Poor technique can resemble treatment failure. A patient may report that the medicine “does nothing” when the soft mist is being released too early, inhaled too quickly, or not inhaled deeply enough.

Doctors also look for a separate explanation when breathlessness suddenly worsens. Infection, pulmonary embolism, heart disease, smoking exposure, poor adherence, and incorrect reliever use can all produce symptoms that should not be attributed automatically to COPD or asthma.

The practical clinical goal is not to remove every symptom. It is to improve baseline airflow, reduce daily limitation, and lower the likelihood of worsening respiratory control within the patient’s wider treatment plan.

Frequently asked questions

Is Spiriva a rescue inhaler?

No. Spiriva is a once-daily maintenance bronchodilator, while a short-acting reliever is used for rapid symptoms. The FDA prescribing information available before 2026 identifies Spiriva Respimat as a maintenance treatment rather than therapy for acute bronchospasm. Use the emergency plan prescribed for sudden severe breathlessness.

How long does Spiriva take to work?

Some people notice easier breathing during the first day, while the full practical benefit becomes clearer after regular use over several days or weeks. The 2023 EMA product information describes tiotropium as a prolonged bronchodilator for daily control rather than an instant reliever. Persistent deterioration needs clinical assessment rather than extra inhalations.

Can Spiriva be used with an inhaled corticosteroid?

Yes, Spiriva Respimat can be used as add-on maintenance treatment in selected asthma plans that already include an inhaled corticosteroid. The 2012 VivaTinA-asthma research programme evaluated tiotropium alongside established controller therapy. Spiriva should not be used to replace an inhaled corticosteroid when that anti-inflammatory treatment has been prescribed.

Does Spiriva cause dry mouth?

Dry mouth is a recognised anticholinergic effect of tiotropium. The 2023 European Medicines Agency product information lists dry mouth among adverse reactions associated with treatment. Water, sugar-free gum, and regular dental care may improve comfort, while persistent swallowing difficulty or severe mouth dryness needs clinical review.

Can Spiriva cause urinary retention?

Yes. Anticholinergic medicines can make urination more difficult, especially in people with bladder-outflow obstruction or prostate enlargement. The 2024 FDA prescribing information warns about urinary retention risk with Spiriva Respimat. New inability to pass urine, painful bladder fullness, or severe lower abdominal discomfort requires urgent medical attention.

Is Spiriva suitable during pregnancy?

Pregnancy requires an individual assessment of the mother’s respiratory control and the potential medicine exposure. The 2023 EMA product information discusses pregnancy and breastfeeding precautions for tiotropium-containing treatment. Poorly controlled asthma or COPD also carries clinical risks, so treatment changes should be planned with the prescribing clinician rather than made abruptly.

What happens if a Spiriva dose is missed?

Take the missed dose when remembered unless the next scheduled dose is near. Do not take two daily doses to compensate. The 2024 FDA prescribing information supports the same practical safety principle for once-daily medicines: avoid dose doubling unless a product-specific clinician instruction says otherwise.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Spiriva: Reviews and Experiences

3.9
Based on 4 reviews
Thandi, 42 Cape Town Three weeks
Verified
Rating: 4 out of 5

Walking uphill became easier, although I noticed dry mouth during the first week and kept sugar-free gum with me.

21 Oct 2026
Liam, Fifty-one Durban Several days
Verified
Rating: 4 out of 5

The inhaler helped my morning chest tightness, but I initially pressed too early and saw the mist outside the mouthpiece. A nurse corrected the breathing technique.

31 Oct 2026
Naledi, sixty-three Johannesburg Roughly one month
Verified
Rating: 4 out of 5

I was waking less often with coughing. Constipation became annoying, so my doctor reviewed my other medicines and changed the timing of one of them.

05 Nov 2026
Michael, thirty-seven Gqeberha One busy week
Verified
Rating: 3.5 out of 5

I missed several doses and thought Spiriva had stopped working. The symptoms improved again after I returned to the once-daily routine, but I still needed my reliever during one flare.

16 Nov 2026

Sources

  1. U.S. Food and Drug Administration (2024). Spiriva Respimat (tiotropium bromide) inhalation spray prescribing information.
  2. European Medicines Agency (2023). Spiriva — Summary of Product Characteristics and product information.
  3. New England Journal of Medicine (2013). Tiotropium Respimat inhaler and the risk of death in COPD.
Get our free app Shop faster and track your orders 4.0 · 598 reviews Install